What Aurore Life Sciences does

Aurore Life Sciences is a privately held, pure-play Active Pharmaceutical Ingredient (API) and intermediates manufacturer headquartered in Hyderabad, India. Founded in 2017, the company operates two manufacturing facilities — the USFDA- and EU-approved Jeedimetla site (approximately 450 KL reactor capacity, five manufacturing blocks, fifteen clean rooms) and the WHO-GMP- and EU-WC-certified Kazhipally greenfield site (approximately 390 KL capacity, three blocks, four clean rooms) — for a combined 840 KL of reactor capacity and 19 clean rooms. Aurore manufactures 76+ APIs across therapeutic categories including antivirals, anti-hypertensives, anti-diabetics, anti-inflammatory, anti-psychotics, anti-coagulants, anti-retrovirals, and cardiovascular drugs, and supports this portfolio with in-house key starting material and intermediate production.

The company's core technology is chemical synthesis and semi-synthesis of APIs with full backward integration from key starting materials to finished APIs, supplemented by specialty capabilities such as cryogenic reactions (used in Dapagliflozin and Empagliflozin manufacturing). R&D and quality infrastructure comprises 60 R&D scientists, 65 analytical experts, and 10 doctorates working with UHPLC, NMR, mass spectrometry, and X-ray crystallography. The regulated product portfolio is backed by 35+ US Drug Master Files, 30+ Certificates of Suitability to the European Pharmacopoeia, and management systems certified to ISO 9001, ISO 14001, and ISO 45001.

Aurore generates revenue through two streams: merchant supply of APIs and intermediates to global formulation manufacturers (quote-based, contract and commercial volumes), and Contract Development and Manufacturing Organization (CDMO) services covering new chemical entities, advanced intermediates, high-potency drugs, and controlled substances from R&D through commercial manufacturing. Customers are global pharmaceutical manufacturers across 22+ countries in North America, Europe, Asia Pacific, the Middle East, Africa, South America, and Oceania; customer logos are not disclosed. The go-to-market is B2B enterprise field sales with direct engagement rather than distributor-led channel activity.

Name

Aurore Life Sciences

Legal name

Aurore Life Sciences

Website

https://aurorels.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

251–500 employees

Short description

Aurore Life Sciences is a Hyderabad, India-based, privately held API and intermediates manufacturer operating two USFDA- and EU-approved plants (840 KL combined capacity) to supply 76+ APIs across multiple therapeutic categories and provide CDMO services to global pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule API Commercial Manufacturing (HLAGAHAB), Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• CDMO services
• Drug intermediates
• API production

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. API & Intermediates Manufacturing: Revenue from manufacturing and selling Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates to global pharmaceutical companies on a contract and commercial basis.
2. CDMO Services: Contract Development and Manufacturing Organization (CDMO) services providing end-to-end solutions from R&D through commercial manufacturing for pharmaceutical clients.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Aurore Life Sciences manufactures Active Pharmaceutical Ingredients (APIs) and intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services to global pharmaceutical companies. The company develops and produces high-quality drug substances and key starting materials, supporting formulation development and commercial-scale manufacturing for the pharmaceutical industry.

Product overview

Aurore Life Sciences is a pure-play API and intermediates manufacturing company driven by R&D excellence with seamless backward integration. The company offers a comprehensive portfolio of 76+ Active Pharmaceutical Ingredients (APIs) across therapeutic categories including antivirals, anti-hypertensives, anti-diabetics, anti-inflammatory, anti-psychotics, anti-coagulants, anti-retrovirals, and cardiovascular drugs. The product portfolio is organized into three main categories: (1) APIs as the core product offering with 35+ USDMFs and 30+ CEPs, (2) pharmaceutical intermediates supporting backward integration for API manufacturing, and (3) CDMO services for contract development and manufacturing of new chemical entities, advanced intermediates, high-potency drugs, and controlled substances.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Manufacture of Active Pharmaceutical Ingredients (drug substances) that provide therapeutic effect in finished pharmaceutical formulations. These APIs are produced for pharmaceutical formulators and global generic and innovator drug manufacturers at commercial scale.
• Pharmaceutical Intermediates Manufacture of drug intermediates and key starting materials used as precursors in the synthesis of Active Pharmaceutical Ingredients. Offered to pharmaceutical companies requiring high-purity chemical intermediates for their API production processes.
• CDMO Services Contract Development and Manufacturing Organization services covering process development, scale-up, and contract manufacturing of APIs and intermediates for pharmaceutical clients seeking custom development and production support.

Quantifiable outcome

• 2 USFDA & EU Approved Facilities
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Divi's Laboratories: Indian API and intermediates manufacturer with strong backward integration and a CDMO segment serving global pharma. Highly comparable to Aurore on product model, customer base, and India-based manufacturing footprint, though at substantially larger scale.
• Aarti Drugs: Indian manufacturer of APIs and intermediates across therapeutic categories including anti-diabetic, cardiovascular, and anti-inflammatory. Comparable on product model and global B2B customer base, though smaller and less CDMO-focused.
• Suven Pharmaceuticals: Indian CRAMS/CDMO company focused on API development and manufacturing for global pharma. Directly comparable on contract API manufacturing model, backward integration, and USFDA-aligned operations.
• Piramal Pharma Solutions: Global CDMO offering integrated API and drug product development services, including high-potency and complex synthesis. Comparable to Aurore on CDMO positioning and complex chemistry capabilities.
• Sai Life Sciences: Indian CDMO providing API development, manufacturing, and analytical services to global innovator and generic pharma. Comparable on CDMO service model, technical complexity, and customer base.
• Laurus Labs: Indian-headquartered API manufacturer and CDMO offering API, intermediates, and formulation services globally. Directly comparable on therapeutic-area breadth, regulatory filings (USDMFs/CEPs), and CDMO exposure.
• Syngene International: Indian CRO/CDMO offering API development, manufacturing, and integrated discovery services to global pharma. Comparable on contract manufacturing model, India-based operations, and high-end chemistry capabilities including cryogenic and high-potency handling.

Broad incumbents

• Aurobindo Pharma: Large Indian pharmaceutical company with a substantial API manufacturing business alongside finished formulations. Overlaps with Aurore on API/intermediates production and USFDA-approved manufacturing, but operates at much greater scale across the full pharma value chain.
• Jubilant Pharmova: India-based pharma company with API and CDMO operations across multiple therapeutic categories. Comparable on API manufacturing and CDMO services, but with broader portfolio including radiopharma and dosage forms.

Emerging players

• Granules India: Indian pharmaceutical company with API manufacturing operations supporting its finished-dose formulation business. Comparable on API/intermediate manufacturing and USFDA exposure, though more formulation-integrated than Aurore.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Aurore-Life-Sciences-100063815271682
• LinkedInlinkedin.com/company/aurore-life-sciences

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurore Life Sciences